Optimal timing of SARS-CoV-2 vaccination prior to cardiovascular surgery under cardiopulmonary bypass.

Publication date: Feb 28, 2024

mRNA vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) became common. We investigated the optimal timing for inoculation against SARS-COV-2 in the candidates for cardiac surgery under cardiopulmonary bypass (CPB). In 100 patients with preoperative vaccination, who underwent CPB surgery between July 2021 and February 2022, the IgG against the receptor binding domain (RBD-IgG), with a threshold of >100 binding antibody unit (BAU)/mL for adequate immunity, was measured. The vaccines, including 87 BNT162b2 (Pfizer/BioNTech) and 13 mRNA-1273 (Moderna), were inoculated at 98. 8 +/- 59. 4 days before surgery. The median RBD-IgG titers before surgery, 1 day after surgery, and 1 month after surgery were 166. 8, 100. 0, and 84. 0 BAU/mL, respectively. The standby interval (SBI) from the vaccination to the surgery showed a significantly negative correlations with the RBD-IgG titer before the surgery (p 100 BAU/mL before surgery was

Concepts Keywords
Coronavirus cardiopulmonary bypass
February coronavirus disease 2019
July IgG antibody
Surgery mRNA vaccine


Type Source Name
disease VO vaccination
disease VO Severe acute respiratory syndrome coronavirus 2
disease VO Cpb
disease VO titer
disease MESH coronavirus disease 2019
disease VO vaccine

Original Article

(Visited 1 times, 1 visits today)